{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:06:14Z","timestamp":1789549574606,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the association between treatment efficacy and immune-related adverse events (irAEs) in patients with solid malignancies receiving adebrelimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data from 46 patients with solid tumors who received adebrelimab between June 2023 and March 2026 were retrospectively collected. Patients were categorized as having experienced irAEs during treatment, and efficacy outcomes were compared between the irAE and non-irAE groups. Logistic regression analysis was used to evaluate the association between irAEs and objective response rate (ORR), whereas the Kaplan\u2013Meier method, Cox regression, and time-dependent Cox models were used to assess the association between irAEs and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 46 patients, 40 (87.0%) experienced treatment-related adverse events (TRAEs), including 5 (10.9%) with grade 3\u20134 events. Eighteen patients (39.1%) experienced irAEs, most of which were grade 1\u20132, with a median onset time of 62 days (IQR, 42\u2013163; range, 22\u2013417 days). The overall ORR and disease control rate (DCR) were 37.0% and 87.0%, respectively. The ORR was higher in the irAE group than in the non-irAE group (61.1% vs. 21.4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.012), whereas no significant difference in DCR was observed between the two groups (94.4% vs. 82.1%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.380). In univariate analysis, irAE occurrence was associated with ORR (OR\u00a0=\u00a05.762, 95% CI: 1.557\u201321.328;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.009); however, after adjustment for the number of treatment cycles, this association did not reach statistical significance (OR\u00a0=\u00a03.847, 95% CI: 0.961\u201315.410;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.057). Neither conventional Cox regression nor time-dependent Cox regression demonstrated a statistically significant association between irAE occurrence and PFS (HR\u00a0=\u00a01.906, 95% CI: 0.710\u20135.113,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.200; HR\u00a0=\u00a02.444, 95% CI: 0.911\u20136.557,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.076, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adebrelimab demonstrated an overall acceptable and manageable safety profile, with most irAEs being low-grade. Although irAE occurrence was associated with a higher ORR, this association was attenuated after adjustment for the number of treatment cycles, and no significant association between irAEs and PFS was observed. The current findings are insufficient to support irAEs as an independent predictor of adebrelimab efficacy, and further validation in larger, multicenter, prospective studies is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1957193","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:18:44Z","timestamp":1789546724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-related adverse events and clinical outcomes in patients with solid tumors treated with adebrelimab: a real-world exploratory study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yifan","family":"Chao","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, The First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyue","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, The First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, The First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanxi Province Cancer Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, The First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-020-00794-x","article-title":"Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: A subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)","volume":"18","author":"Takahashi","year":"2021","journal-title":"Esophagus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2022.09.222","article-title":"Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II to III NSCLCs: An open-label, multicenter, phase 1b trial","volume":"18","author":"Yan","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: A phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.91737","article-title":"Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study","volume":"12","author":"Chen","year":"2023","journal-title":"Elife"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: A systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad154","article-title":"Immune-related adverse events and clinical outcomes in advanced urothelial cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Sanda","year":"2023","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13073-019-0652-8","article-title":"Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach","volume":"11","author":"Khan","year":"2019","journal-title":"Genome Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-299","article-title":"Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1408755","article-title":"Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: A meta-analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: Pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-16446-9","article-title":"Immune-related adverse events with cancer clinical benefits: A systematic review and meta-analysis","author":"Li","year":"2026","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/apt.70427","article-title":"Meta-analysis: Immune-related adverse events are associated with improved effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"63","author":"Liu","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1957193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:18:48Z","timestamp":1789546728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1957193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1957193"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1957193","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1957193"}}